Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
FDF
0
Australia
0
South Africa
0
Listed Dossiers
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
1. Gs 9137
2. Gs-9137
3. Gs9137
4. Jtk 303
5. Jtk-303
6. Jtk303
7. Vitekta
1. 697761-98-1
2. Gs-9137
3. Jtk-303
4. Vitekta
5. Gs 9137
6. Elvitegravir (gs-9137)
7. Evg
8. Unii-4gdq854u53
9. (s)-6-(3-chloro-2-fluorobenzyl)-1-(1-hydroxy-3-methylbutan-2-yl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid
10. 6-(3-chloro-2-fluorobenzyl)-1-[1(s)-(hydroxymethyl)-2-methylpropyl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid
11. Chebi:72289
12. 6-[(3-chloro-2-fluorophenyl)methyl]-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxoquinoline-3-carboxylic Acid
13. Chembl204656
14. 4gdq854u53
15. D06677
16. 6-(3-chloro-2-fluorobenzyl)-1-((2s)-1-hydroxy-3-methylbutan-2-yl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid
17. 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid
18. Jtk 303
19. 3-quinolinecarboxylic Acid, 6-((3-chloro-2-fluorophenyl)methyl)-1,4-dihydro-1-((1s)-1-(hydroxymethyl)-2-methylpropyl)-7-methoxy-4-oxo-
20. 6-(3-chloro-2-fluorobenzyl)-1-[(1s)-1-(hydroxymethyl)-2-methylpropyl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid
21. Jtk303
22. Elvitegravir [usan]
23. Gs9137
24. Elvitegravir [usan:inn]
25. Elvitegravirum
26. 6-(3-chloro-2-fluorobenzyl)-1-((1s)-1-(hydroxymethyl)-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid
27. 6-[(3-chloro-2-fluoro-phenyl)methyl]-1-[(1s)-1-(hydroxymethyl)-2-methyl-propyl]-7-methoxy-4-oxo-quinoline-3-carboxylic Acid
28. Elv
29. Vitekta (tn)
30. Elvitegravir [mi]
31. Elvitegravir (jan/usan)
32. Elvitegravir [inn]
33. Elvitegravir [jan]
34. Elvitegravir (jtk-303)
35. Elvitegravir [vandf]
36. Elvitegravir [mart.]
37. Mls006011136
38. Elvitegravir [who-dd]
39. Schembl726252
40. Gtpl11574
41. Bcpp000242
42. Dtxsid101021650
43. Elvitegravir [orange Book]
44. Ex-a1542
45. Bdbm50183273
46. Mfcd11846134
47. S2001
48. Vitekta Component Elvitegravir
49. Zinc13682481
50. Elvitegravir; Gs9137; Jtk 303
51. Stribild Component Elvitegravir
52. Akos025396642
53. Bcp9000642
54. Ccg-269208
55. Compound 2 [pmid: 18281931]
56. Cs-0439
57. Db09101
58. Elvitegravir (gs-9137, Jtk-303)
59. Elvitegravir Component Of Genvoya
60. Elvitegravir Component Of Vitekta
61. Elvitegravir Component Of Stribild
62. Ncgc00346565-01
63. Ncgc00346565-04
64. Ncgc00346565-08
65. Ac-29947
66. As-16986
67. Hy-14740
68. Smr004702914
69. Elvitegravir 100 Microg/ml In Acetonitrile
70. A4070
71. Sw219721-1
72. Ec-000.2332
73. Ab01274749-01
74. Ab01274749_02
75. J-518006
76. Q2740966
77. Brd-k54472332-001-01-8
78. 3-quinolinecarboxylic Acid, 6-[(3-chloro-2-fluorophenyl)methyl]-1,4-dihydro-1-[(1s)-1-isopropyl-2-hydroxyethyl]-7-methoxy-4-oxo-
79. 6-(3-chloro-2-fluorobenzyl)-1-[(s)-1-hydroxymethyl-2-methylpropyl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid
Molecular Weight | 447.9 g/mol |
---|---|
Molecular Formula | C23H23ClFNO5 |
XLogP3 | 5.3 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 7 |
Exact Mass | 447.1248787 g/mol |
Monoisotopic Mass | 447.1248787 g/mol |
Topological Polar Surface Area | 87.1 Ų |
Heavy Atom Count | 31 |
Formal Charge | 0 |
Complexity | 702 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Elvitegravir in combination with an HIV protease inhibitor coadministered with ritonavir and with other antiretroviral drug(s) is indicated for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults.
FDA Label
Vitekta co-administered with a ritonavir-boosted protease inhibitor and with other antiretroviral agents, is indicated for the treatment of human-immunodeficiency-virus-1 (HIV-1) infection in adults who are infected with HIV-1 without known mutations associated with resistance to elvitegravir.
Anti-HIV Agents
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. (See all compounds classified as Anti-HIV Agents.)
Anti-Retroviral Agents
Agents used to treat RETROVIRIDAE INFECTIONS. (See all compounds classified as Anti-Retroviral Agents.)
Integrase Inhibitors
Compounds which inhibit or antagonize biosynthesis or actions of integrase. (See all compounds classified as Integrase Inhibitors.)
J05AX11
J - Antiinfectives for systemic use
J05 - Antivirals for systemic use
J05A - Direct acting antivirals
J05AJ - Integrase inhibitors
J05AJ02 - Elvitegravir
Absorption
Following oral administration of elvitegravir and ritonavir with food, in HIV-1 infected subjects, peak elvitegravir plasma concentrations were observed approximately 4 hours post-dose.
Route of Elimination
Following oral administration of [14C]elvitegravir/ritonavir, 94.8% of the dose was recovered in feces, while 6.7% was recovered in urine as metabolites.
Elvitegravir undergoes primarily oxidative metabolism via CYP3A, and is secondarily glucuronidated via UGT1A1/3 enzymes. Metabolites are found in the plasma at very low concentrations, displayed considerably lower anti-HIV activity, and did not contribute to the overall antiviral activity of elvitegravir.
The median terminal plasma half-life following administration of elvitegravir and ritonavir was approximately 8.7 hours.
Elvitegravir is an HIV-1 integrase strand transfer inhibitor (INSTI). Integrase is an HIV-1 encoded enzyme that is required for viral replication. Inhibition of integrase prevents the integration of HIV-1 DNA into host genomic DNA, blocking the formation of the HIV-1 provirus and propagation of the viral infection. Elvitegravir does not inhibit human topoisomerases I or II.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 34649
Submission : 2020-03-30
Status : Active
Type : II
Date of Issue : 2022-06-17
Valid Till : 2025-07-02
Written Confirmation Number : WC-0082
Address of the Firm :
GDUFA
DMF Review : Reviewed
Rev. Date : 2017-01-08
Pay. Date : 2016-09-29
DMF Number : 30772
Submission : 2016-08-30
Status : Active
Type : II
Date of Issue : 2019-10-15
Valid Till : 2022-08-08
Written Confirmation Number : WC-0383A4
Address of the Firm :
NDC Package Code : 69766-015
Start Marketing Date : 2016-07-28
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 31090
Submission : 2016-12-27
Status : Active
Type : II
NDC Package Code : 69766-015
Start Marketing Date : 2016-07-28
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 32456
Submission : 2017-12-20
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25187
Submission : 2011-10-21
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-03-31
Pay. Date : 2013-12-09
DMF Number : 27727
Submission : 2013-12-27
Status : Active
Type : II
NDC Package Code : 65015-839
Start Marketing Date : 2015-03-03
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2015-10-22
Pay. Date : 2015-07-28
DMF Number : 29558
Submission : 2015-08-28
Status : Active
Type : II
NDC Package Code : 65015-839
Start Marketing Date : 2015-03-03
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Date of Issue : 2019-07-26
Valid Till : 2022-05-05
Written Confirmation Number : WC-0362
Address of the Firm :
NDC Package Code : 69037-0002
Start Marketing Date : 2012-08-27
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Date of Issue : 2021-10-05
Valid Till : 2022-07-02
Written Confirmation Number : WC-0082A11
Address of the Firm :
(R)-(-)-2-Amino-3-methyl-1-butanol
CAS Number : 4276-09-9
End Use API : Elvitegravir
About The Company : USV is a leading health care company with focus on Active Pharmaceutical Ingredients (marketed globally with emphasis on regulated markets of USA, European Unio...
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Elvitegravir manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Elvitegravir, including repackagers and relabelers. The FDA regulates Elvitegravir manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Elvitegravir API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Elvitegravir manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Elvitegravir supplier is an individual or a company that provides Elvitegravir active pharmaceutical ingredient (API) or Elvitegravir finished formulations upon request. The Elvitegravir suppliers may include Elvitegravir API manufacturers, exporters, distributors and traders.
click here to find a list of Elvitegravir suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Elvitegravir DMF (Drug Master File) is a document detailing the whole manufacturing process of Elvitegravir active pharmaceutical ingredient (API) in detail. Different forms of Elvitegravir DMFs exist exist since differing nations have different regulations, such as Elvitegravir USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Elvitegravir DMF submitted to regulatory agencies in the US is known as a USDMF. Elvitegravir USDMF includes data on Elvitegravir's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Elvitegravir USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Elvitegravir suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Elvitegravir Drug Master File in Korea (Elvitegravir KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Elvitegravir. The MFDS reviews the Elvitegravir KDMF as part of the drug registration process and uses the information provided in the Elvitegravir KDMF to evaluate the safety and efficacy of the drug.
After submitting a Elvitegravir KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Elvitegravir API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Elvitegravir suppliers with KDMF on PharmaCompass.
A Elvitegravir written confirmation (Elvitegravir WC) is an official document issued by a regulatory agency to a Elvitegravir manufacturer, verifying that the manufacturing facility of a Elvitegravir active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Elvitegravir APIs or Elvitegravir finished pharmaceutical products to another nation, regulatory agencies frequently require a Elvitegravir WC (written confirmation) as part of the regulatory process.
click here to find a list of Elvitegravir suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Elvitegravir as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Elvitegravir API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Elvitegravir as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Elvitegravir and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Elvitegravir NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Elvitegravir suppliers with NDC on PharmaCompass.
Elvitegravir Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Elvitegravir GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Elvitegravir GMP manufacturer or Elvitegravir GMP API supplier for your needs.
A Elvitegravir CoA (Certificate of Analysis) is a formal document that attests to Elvitegravir's compliance with Elvitegravir specifications and serves as a tool for batch-level quality control.
Elvitegravir CoA mostly includes findings from lab analyses of a specific batch. For each Elvitegravir CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Elvitegravir may be tested according to a variety of international standards, such as European Pharmacopoeia (Elvitegravir EP), Elvitegravir JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Elvitegravir USP).
LOOKING FOR A SUPPLIER?